This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

3 Reasons Why Rite Aid Is Right On

Stocks in this article: CVS RAD WAG

The relatively cheaper generic drugs were a perfect match for the post-financial crisis period, when organizations were looking for ways to reduce their health care expenditure. As a result, generic drugs have taken over the American market and now account for nearly 80% of all subscriptions filled.

The industry has been shifting toward generics, but the pace of that shift has been slowing down. That being said, it should also be noted that around $15 billion in branded drugs will come off patent in the next couple of years. This means that despite the slow pace, generics could continue to slowly increase their share of the market with the addition of these new and previously unavailable generic drugs.

Although these drugs carry higher margins, they are considerably lower priced. As a result, the rise of generics has an adverse impact on the top-line growth of the big drugstore chains: Rite Aid, Walgreen (WAG) and CVS Caremark. The slowdown in the introduction of generics and increasing competition in this category could be a drag on the bottom line as well.

These were some of the reasons behind Rite Aid's reduction of its earnings forecast. The second biggest player in the industry, Walgreen, is facing similar problems. In its previous quarterly results, Walgreen reported an increase in earnings but its gross margin slipped 1.3 percentage points, to 28.1%.

Three Reasons For Optimism

Although Rite Aid could struggle with top-line growth, there is still a lot to look forward to.

Firstly, the business has been working on its cost-control measures to drive its earnings growth. Its selling, general and administrative expenses, as a percentage of sales, have fallen to 25.6% in the previous quarter from 26.1% in the prior year. Further improvements will lead to better profitability.

Secondly, Rite Aid has been remodeling its stores into the new Wellness format, with more pharmacy services and healthier products. A typical Wellness store has 3.2% better front-end same-store sales than a non-Wellness store. The business has so far converted a quarter of its 4,600 stores into Wellness stores. They will convert nearly 500 more stores to Wellness by next fiscal year. This will give a boost to Rite Aid's revenues and earnings in the coming years.

Thirdly, Rite Aid's poor financial health has been a cause for concern, but the business has been moving in the right direction. In the previous quarter, the company cut its total debt by $44.1 million. Its debt is a lofty 4.5 times its adjusted earnings ratio. But that has improved significantly, from 5.6 times in the same quarter of fiscal 2013. With its strong ability to generate free cash flow, Rite Aid could significantly reduce its debt in the next three to five years.

In short, I still like Rite Aid.

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,625.35 -47.25 -0.27%
S&P 500 2,048.20 -3.62 -0.18%
NASDAQ 4,751.31 -6.5690 -0.14%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs